Quality of life evidence for patients with Alzheimer’s disease: use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon®
This paper utilises the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s disease to establish a relationship between disease progression and quality of life measures, and the author also compares his results to findings from the literature review about Alzheimer’s patient utility.
|Date of creation:||2001|
|Date of revision:|
|Contact details of provider:|| Postal: |
Web page: https://mpra.ub.uni-muenchen.de
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:pra:mprapa:29729. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Ekkehart Schlicht)
If references are entirely missing, you can add them using this form.